Drug-resistant tuberculosis treatment


Recommendations in the 2019 updat


Download 1.73 Mb.
Pdf ko'rish
bet115/115
Sana05.02.2023
Hajmi1.73 Mb.
#1167595
1   ...   107   108   109   110   111   112   113   114   115
Bog'liq
9789240007048-eng

Recommendations in the 2019 updat
e
Recommendations in the curr
ent updat
e
One or mor
e o
f the following tr
eatment adher
ence inter
ventions 
(complementar
y and not mutually exclusive) may be o
ffer
ed to 
patients on TB tr
eatment or to health-car
e
pr
ovider
s:
a.
tracer
s
73
and/or digital medication monitor 
74
(conditional 
recommendation, ver
y low cer
tainty in the
 
evidence);
b.
material suppor
t
75
to the patient
 (conditional r
ecommendation, 
moderate cer
tainty in the
 
evidence);
c.
psychological suppor
t
76
to the patient
 (conditional 
recommendation, low cer
tainty in the
 
evidence);
d.
staff education 
(conditional r
ecommendation, low cer
tainty in 
the evidence).
77
8.3 One or mor
e o
f the following tr
eatment adher
ence inter
ventions 
(complementar
y and not mutually exclusive) may be o
ffer
ed to patients on TB 
treatment or to health car
e
pr
ovider
s:
a.
tracer
s
73
and/or digital medication monitor
74
 (conditional r
ecommendation, 
ver
y low cer
tainty in the
 
evidence);
b.
material suppor
t
75
to the patient
 (conditional r
ecommendation, moderate 
cer
tainty in the
 
evidence);
c.
psychological suppor
t
76 
to the patient 
(conditional r
ecommendation, low 
cer
tainty in the
 
evidence);
d.
staff education
77
 (conditional r
ecommendation, low cer
tainty in the
 
evidence).
 
(no
 
change)
73
Tracer
s r
efer to communication with the patient, including home visits or via shor
t message ser
vice (SMS), telephone (voice) call.
74
A digital medication monitor is a device that can measur
e the time between openings o
f the pill bo
x. The medication monitor can have audio r
eminder
s or send an SMS to r
emind the patient to take medications,
along with r
ecor
ding when the pill bo
x is
opened.
75
Material 
suppor
t can be food or financial 
suppor
t: meals, food baskets, 
food supplements, 
food voucher
s, 
transpor
t subsidies, 
living 
allowance, 
housing 
incentives or financial 
bonus. 
This 
suppor
t addr
esses 
the 
indir
ect costs incurr
ed by patients or their attendants in or
der to access health ser
vices and, possibly
, tries to mitigate the consequences o
f income loss r
elated to the
disease.
76
Psychological suppor
t can be counselling sessions or peer
-gr
oup
suppor
t.
77
Staff education can be adher
ence education, char
t or visual r
eminder
s, educational tools and desktop aids for decision-making and
reminder
s.


Supplementary Table
98
Recommendations in the 2019 updat
e
Recommendations in the curr
ent updat
e
The following tr
eatment administration options may be o
ffer
ed to 
patients on TB
treatment:
a.
Community- or home-based dir
ectly-obser
ved tr
eatment 
(DO
T) is r
ecommended over health facility-based DO

or unsuper
vised tr
eatment
 (conditional r
ecommendation, 
moderate cer
tainty in the
 
evidence).
b.
DO
T administer
ed by trained lay pr
ovider
s or health-
car
e worker
s is r
ecommended over DO
T administer
ed by 
family member
s or unsuper
vised tr
eatment
 (conditional 
recommendation, ver
y low cer
tainty in the
 
evidence).
c.
Video-obser
ved tr
eatment (V
O
T) may r
eplace DO
T when 
video communication technology is available, and it can be appr
opriately or
ganized and operated by health-car

pr
ovider
s and patients
 (conditional r
ecommendation, ver
y low 
cer
tainty in the
 
evidence).
8.4 The following tr
eatment administration options may be o
ffer
ed to patients on 
TB
treatment:
a.
Community- or home-based dir
ectly obser
ved tr
eatment (DO
T) is 
recommended over health facility-based DO
T or unsuper
vised tr
eatment 
(conditional r
ecommendation, moderate cer
tainty in the
 
evidence).
b.
DO
T administer
ed by trained lay pr
ovider
s or health car
e worker
s is 
recommended over DO
T administer
ed by family member
s or unsuper
vised 
treatment
 (conditional r
ecommendation, ver
y low cer
tainty in the
 
evidence).
c.
Video-obser
ved tr
eatment (V
O
T) may r
eplace DO
T when the video 
communication technology is available, and it can be appr
opriately 
or
ganized and operated by health car
e pr
ovider
s and patients.
 (conditional 
recommendation, ver
y low cer
tainty in the
 
evidence)
 
(no
 
change)
Patients with MDR-TB should be tr
eated using mainly 
ambulator
y car
e rather than models o
f car
e based principally 
on hospitalization 
(conditional r
ecommendation, ver
y low-
quality
 
evidence).
8.5 P
atients with multidrug-r
esistant TB (MDR-TB) should be tr
eated using mainly 
ambulator
y car
e rather than models o
f car
e based principally on
hospitalization.
(Conditional r
ecommendation, ver
y low quality
 
evidence).
 
(no
 
change)
A decentralized model o
f car
e is r
ecommended over a 
centralized model for patients on MDR-TB tr
eatment
 (conditional 
recommendation, ver
y low cer
tainty in the
 
evidence).
8.6 A decentralized model o
f car
e is r
ecommended over a centralized model for 
patients on MDR-TB
treatment.
(Conditional r
ecommendation, ver
y low cer
tainty in the evidence). 
 
(no
 
change)




WHO consolidated
guidelines 
on tuber
culosis Module 4: T
reatment
For further information, please contact:
World Health Organization
20, Avenue Appia CH-1211 Geneva 27 Switzerland
Global TB Programme
Web site: www.who.int/tb

Document Outline

  • Supplementary Table
  • References
  • Research gaps
  • Recommendations 
    • Section 1. Regimen for rifampicin-susceptible, isoniazid-resistant tuberculosis 
    • Section 2. Shorter all-oral bedaquiline-containing regimen for multidrug- or rifampicin-resistant tuberculosis
    • Section 3. Longer regimens for multidrug- or rifampicin-resistant tuberculosis 
    • Section 4. The bedaquiline, pretomanid and linezolid (BPaL) regimen for multidrug-resistant tuberculosis with additional fluoroquinolone resistance
    • Section 5. Monitoring patient response to MDR-TB treatment using culture
    • Section 6. Starting antiretroviral therapy in patients on second-line antituberculosis regimens
    • Section 7. Surgery for patients on MDR-TB treatment
    • Section 8. Care and support for patients with MDR/RR-TB
  • Executive summary
  • Definitions
  • Abbreviations and acronyms
  • Acknowledgements
  • Introduction

Download 1.73 Mb.

Do'stlaringiz bilan baham:
1   ...   107   108   109   110   111   112   113   114   115




Ma'lumotlar bazasi mualliflik huquqi bilan himoyalangan ©fayllar.org 2024
ma'muriyatiga murojaat qiling